Phone: 040-23418836

040-40272617

Mobile: 98482 71555

LIMITED REVIEW REPORT

To,
The Board of Directors,
SAAMYA BIOTECH (INDIA) LTD

We have reviewed the accompanying statement of Un-audited Financial Results of SAAMYA BIOTECH (INDIA) LTD for the quarter ended and half year ended 30th September, 2017attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular NO. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad

Date: 14th December, 2017

For M M REDDY & CO., Chartered Accountants

M. Madhusudhana Redd

Membership No. 2



CIN: L24239AP2002PLC039449

November 14, 2018

To

Corporate Relations Department, BSE LTD, P J Towers, Dalal Street, Mumbai - 400001.

Sirs,

Sub: Q2 Unaudited Financial Results - Reg...

Ref: Scrip Code - 532905

Please find herewith attached Un-audited financial results for the first quarter ending 30th September 2017 along with Limited Review Report. The Board Meeting Commenced at 4 PM and concluded at 5:15 PM. Please take on record the same.

Thanking You,

For SAAMYA BIOTECH (INDIA) LIMITED

Director





Saamya Biotech (India) Ltd.

	SA	AMYA BIOT	ECH (INDIA)) LTD				
	Statement of Un-A	udited Result	s for the Qua	rter ended 30.	09.2017			
S.No.	Particulars	0 1 7 1 1					unts in Lakh	
J. 10.	rarticulars	Quarter Ended			Half year Ended		Year Ende	
		30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017	
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited	
I.	Revenue from Operations		-				-	
II.	Other Income	-	-		-		-	
III.	Total income (I+II)		-	-,	-	-		
	Expenses			<u> </u>				
	(a) Cost of Materials consumed	-	-	-	-	-	-	
	(b) Purchase of stock-in-trade	-	-	-	, -	-	-	
	(c) Changes in inventories of finished							
	goods, work-in-progress and stock-in-trade				-	-	-	
	(d) Employee benefits expense	0.53	0.56	2.49	1.09	4.98	9.90	
	(e) Finance Cost	-	-	0.03	-	0.06	0.74	
	(f) Depreciation and amortisation expense	_		22.50	_	44.99	936.63	
	(h)Other expenses	0.25	0.25	6.30	0.50	6.97	. 3,165.57	
	Total Expenses	0.78	0.81	31.32	1.59	57.00	4,112.90	
٧.	Profit / (Loss) before and exceptional items	0.70	0.01	31.52	1.57	37.00	4,112.7	
	and Tax (III-IV)	(0.78)	(0.81)	(31.32)	(1.59)	(57.00)	(4,112.9)	
	Exeptional Items	-	-			1 -	_	
VII	Profit / (Loss) from before tax (V-VI)	(0.78)	(0.81)	(31.32)	(1.59)	(57.00)	(4,112.90	
VIII.	Tax expense	(6176)	(0.01)	(31.32)	(1.57)	(37.00)	(4,112.70	
	Current Tax	-	in -	-	-			
	Deferred Tax	-	-		-	-	51.91	
X	Net Profit / (Loss) after Tax (VII-VIII)	(0.78)	(0.81)	(31.32)	(1.59)	(57.00)		
	Other Comprehensive Inocme	(0.1.5)	(0.02)	(01.02)	(1.57)	(37.00)	(4,164.8)	
	Items that will not be reclasified to Profit or					-		
	Loss	-	-	-	,			
	Items that will be reclasified to Profit or Loss	_						
	Total Comprehensive Income	(0.78)	(0.81)	(31.32)	(1.50)	-	-	
VII	Paid-up equity share capital	(0.70)	(0.01)	(31.32)	(1.59)	(57.00)	(4,164.8)	
ΛII	(Face Value of Rs. 10/- per share)	2,488.25	2,488.25	2,488.25	2,488.25	2 400 2-		
XIII	Earnings Per Equity Share of face value of	2,700.23	2,700.23	2,400.23	2,488.23	2,488.25	2,488.2	
	Rs.10/- each)							
	a) Basic & Diluted (In Rs.)	(0.00)	(0.00)	(0.13)	(0.01)	(0.00)		
	a) Basic & Diluted (In Rs.) (0.00) (0.00) (0.13) (0.01) (0.23) (16.							
	14.1 1 .2017 Hyderabad	FOR SAAMYA BIO TECH PRIVATE LIMITED						
. 1400.		For SAAMYA BIO TECH PRIVATE LIMITED Dr. Y. Manivardhan Reddy Managing Director						

Corporate Office: Plot No. 391- D. Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel: +91-40-2355 1601 / 1604. Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Webiste: www.saamyabiotech.com

Regd. Office: Suite 104-106. Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9832 / 9241 Fax: +91-40-2339 5214 e-mail: saamyaindia@saamyabiotech.com



🕞 Saamya Biotech (India) Ltd.

NOTES:

- 1 The above results were reviewed by the Audit Committee of Directors and taken on record by the Board of Directors at their meeting 2 The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurent principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with teh relevant rules issued thereunder and other accounting propouncements generally accepted in India. The Ind-AS Compliant Standardlone Financial results for the corresponding quarter ended June 30, 2016 have been stated in terms of SEBI Circular dated July, 05, 2016.
- 3 Reconciliation of results between previously reported (referred to as "Previous GAAP") and Ind-AS for the corresponding quarter and Half Year ended September 30, 2016 is as under;

Particulars	Quarter ended 30th Sep, 2016	Half Year 30th Sep, 2016
Net Profit/(Loss) after Tax under Indian		
GAAP	-31.32	-57.00
Details of Ind-As Adjustments		57,00
Impairment of Fixed Assets	_	
Other		
Net Profit for the period as per Ind-AS	-31.32	-57.00
Add: Other Comprehensive Income		-
Total Comprehensive Income for the Period as		
per Ind-AS	-31.32	-57.00

4 The results are also available on the webiste of the Company www.pochiraju.co.in.

POERAB

During the quartere ended 3 complaints received and 1 Compliant pending for resolve.

6 The Company is not operating hence there are no separate reportable segments as per Ind AS -108 "Operating Segments"

Station: Hyderabad Date: 14.12.2017

For SAAMYA BIO TECH PRIVATE LIMITED

Y. Manivardhan Reddy

aging Director



Saamya Biotech (India) Ltd.

	SAAMYA BIOTECH (INDIA) L Balance Sheet as at 30th September 2	71 D 017				
_	Amount in Lakhs					
	Particulars	As at 30-09-2017	As at 31-03-2017			
	ASSETS:	30-03-2017	31-03-2017			
1	NON-CURRENT ASSETS:	1 1				
	(a) Property, Plant and Equipment	17.27	17			
- 1	(b) Capital work-in-progress	1,825.99	1,825			
-	(c) Investment Property	1,025,55	1,023			
	(d) Goodwill					
- [(e) Other Intangible Assets	1 . 1				
-	(f) Intangible Assets under development	1 . 1				
-	(g) Biological Assets other than bearer plants					
-	(h) Financial Assets					
- 1	(i) Investments					
-	(ii) Loans	15.99	15.			
1	(iii) Others					
-	(i) Deferred tax assets (net)					
١	(j) Other non-current assets	0.89	0.			
١,	CUDDENT A COPTO	1,860.13	1,860.			
1	CURRENT ASSETS:					
-	(a) Inventories (b) Financial Assets	- 1	-			
-	(i) Investments	1				
-	(ii) Trade receivables	- 1				
-	(iii) Coch and coch and in the	1,860.92	1,860.			
-	(iii) Cash and cash equivalents	0.75	0.1			
-	(iv) Bank balances other than (iii) above (v) Loans	-				
-	(vi) Others (to be specified)	65.51	65.			
-	(c) Current Tax Assets (Net)	-	-			
-	(d) Other current assets	-				
١	(3) Street current assets	•	•			
4	TOTAL	1,927.17 3,787.30	1,927.1 3,787.3			
,	EQUITY AND LIABILITIES:		0,70710			
	EQUITY:					
1	(a) Equity Share Capital					
-	(b) Other Equity	2,488.25	2,488.2			
1	(b) Other Equity	-3,828.45	-3,826.8			
ı	LIABILITIES:	-1,340.20	-1,338.6			
	NON-CURRENT LIABILITIES:					
ľ	(a) Financial Liabilities					
1	(i)Borrowings	324.01				
ı	(ii)Trade Payables	324.01	324.0			
1	(iii)Other financial liabilities (other than those specified in item (b),	•	-			
ı	to be specified)	•//				
ı	(b) Provisions					
	(c) Deferred tax liabilities (Net)	<u>.</u> [•			
	(d) Other non-current liabilities	: 1	•			
		324.01	3310			
C	CURRENT LIABILITIES:	227.01	324.0			
	(a) Financial Liabilities					
	(i)Borrowings		_			
	(ii)Trade payables	.	-			
1	(iii)Other financial liabilities (other than those specified in item (c))	4,679.66	4,679.6			
	(b) Other current liabilities	1.59	-,0.7.0			
1	(c) Provisions	7.87	7.8			
	(d) Current Tax Liabilities (Net)	114.38	114.3			
	T	4,803.50	4,801.9			
T	14.142017 Hyderabad For SAAM' 4. How	3,787.30	3,787.3			
	OTECH FOR SAAM	YA BIOTECH (INDIA				
e:	14.142017 BIO 2017					
e:	14.1 <u>4.2017</u> Hyderabad A A A A A A A A A A A A A A A A A A A	- ullinoin	Redder			
	IS IN IP		7			
	[4] (A) [7]	Dr. Y. Manivardhan F	Reddy U			
	A COURT					

Corporate Office: Plot No. 391- D. Road No 81, Phase - III, Jubilee Hills, Hyderabad - 500 033, A.P., India. Tel: +91-40-2355 1601 / 1604. Fax: +91-40-2354 1127, email: info@saamyabiotech.com, saamyabiotechltd@yahoo.com, Webiste: www.saamyabiotech.com

Regd. Office: Suite 104-106. Lumbini Enclave, Opp. NIMS, Punjagutta, Hyderabad - 500 082, A.P., India. Tel: +91-40-2339 9832 / 9241 Fax: +91-40-2339 5214 e-mail: saamyaindia@saamyabiotech.com